Embolization, Inc., Polymer-Based Coil Demonstrates Success in Limited-Market Release

-- Coils minimize artifacts in imaging with high packing density --

BOULDER, Colo., April 2, 2026 /PRNewswire/ -- The novel, radiopaque, polymer-based embolic coil from Embolization, Inc., is demonstrating consistent success in its limited-market release, with use cases topping 70 coils.

In all cases, across four institutions and physicians, Embolization's Nitinol Enhanced Device (NED) has shown consistent performance across males and females, ages 21-80, in venous and arterial applications.

The FDA-cleared coil is a vascular embolization device intended for arterial and venous embolization in peripheral vasculature. Vascular embolization is a minimally invasive procedure where a physician intentionally blocks a blood vessel using tiny materials such as coils, particles or glue. This stops bleeding, reduces blood flow to tumors, or prevents damage from abnormal blood vessels, and is often used instead of surgery because it is safer, quicker to recover from and very precise.  

Artifact minimization in CT, MRI imaging
Using proprietary shape-memory biocompatible polymers, Embolization's coil devices have demonstrated improved vascular occlusion while minimizing artifacts in CT and MRI imaging that occur with traditional metal devices. "The NED does everything a traditional metal coil does, but with our novel, radiopaque polymer," says Jim Kasic, who serves as CEO of Embolization. The coils, he explains, remain radiopaque under fluoroscopy even though the CT/MRI imaging artifact is minimal.

Mark J. Garcia, M.D., is an interventional radiologist who has used the coils in several procedures at EndoVascular Consultants in Wilmington, Delaware. "The Embolization device is very effective in what it does, successfully occluding vessels quickly," he states.

Enhanced packing density
Garcia also notes the ability of the coils to pack tightly. "We are seeing much better pack density than the coils that are on the market." That, he explains, leads to the need for fewer coils in a case, and ultimately lower cost.

Kasic echoes Garcia's sentiments. "We are seeing excellent results, confirming that this development represents the next generation in embolic coils."

Additional indications
Kasic also notes the opportunity for expanded future use of the company's proprietary polymer formulation. "Although indicated for peripheral vascular indications, the same technology has the potential for application in a number of other medtech devices, including indications in neurology. "This technology can also serve as a foundational technology applicable to a wide variety of implantable products where reduced imaging artifacts are valuable to patients and practitioners."

Embolization, Inc. (www.embolizationinc.com)
Embolization, Inc., is a medical device company based in Boulder, Colorado. With expertise in radiopaque shape-memory biocompatible polymers, the business specializes in the development of minimally invasive medical devices for peripheral vascular and neurovascular uses in the interventional radiology market. The company received 510(k) clearance from the U.S. Food and Drug Administration for its Nitinol Enhanced Device (NED) in 2025.

Media contact: Aimee Bennett, [email protected], 303-843-9840

SOURCE Embolization, Inc.